Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Genomics & Proteomics
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Cancer Genomics & Proteomics

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin

immunotherapy

  • Open Access
    Macrophage-related Genomic Signatures Predict HCC Prognosis and Therapy Response
    WENTAO ZHONG, LINQIANG DUAN, FENG ZHANG, CHANGGUI ZOU, JUNYI QIU, SHIXIONG HU, MIN YU and ZI YIN
    Cancer Genomics & Proteomics May 2026, 23 (3) 503-529; DOI: https://doi.org/10.21873/cgp.20587
  • Open Access
    CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms
    UMAR WAZIR, AMBER X. LI, CAROLYN CAI WANG, HENSON HAN GAO, TRACEY A. MARTIN, WEN G. JIANG and KEFAH MOKBEL
    Cancer Genomics & Proteomics July 2025, 22 (4) 557-563; DOI: https://doi.org/10.21873/cgp.20521
  • Open Access
    Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors
    TOMOYUKI ISHIGURO, KAZUYUKI TAKEDA, DAISUKE TAKAYANAGI, EMIKO MURA, RISAKO SUZUKI, TOSHIAKI TSURUI, NANA IRIGUCHI, YUYA HIRASAWA, RYOTARO OHKUMA, MASAHIRO SHIMOKAWA, HIROTSUGU ARIIZUMI, YUTARO KUBOTA, ATSUSHI HORIIKE, MASAHIKO IZUMIZAKI, SATOSHI WADA, KIYOSHI YOSHIMURA, ROBERT M. HOFFMAN and TAKUYA TSUNODA
    Cancer Genomics & Proteomics January 2025, 22 (1) 1-12; DOI: https://doi.org/10.21873/cgp.20481
  • Open Access
    GD2 in Breast Cancer: A Potential Biomarker and Therapeutic Target
    KEFAH MOKBEL
    Cancer Genomics & Proteomics November 2024, 21 (6) 549-556; DOI: https://doi.org/10.21873/cgp.20471
  • Open Access
    The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience
    JAVIER TORRALVO, ALEX FRIEDLAENDER, VERANE ACHARD and ALFREDO ADDEO
    Cancer Genomics & Proteomics November 2019, 16 (6) 577-582; DOI: https://doi.org/10.21873/cgp.20160
  • Open Access
    Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes
    SANGSU SHIN, MIOK KIM, SEON-JIN LEE, KANG-SEO PARK and CHANG HOON LEE
    Cancer Genomics & Proteomics September 2017, 14 (5) 349-362;
Cancer & Genome Proteomics

© 2026 Cancer Genomics & Proteomics

Powered by HighWire